Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

EP: 3.When to Switch to More Efficacious Agents

EP: 4.Real-World Experiences With Faricimab

EP: 5.Real-World Experiences With Aflibercept 8mg

Now Viewing

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

Summary

In this segment, the discussion centers on the efficacy and durability of different anti-VEGF agents, specifically aflibercept 2 mg, 8 mg, and faricimab. Diana Do, MD emphasizes the challenges in making direct head-to-head comparisons between these agents, as they were not tested against each other in clinical trials with the same design. The focus shifts particularly to durability gains between therapies, highlighting the need for new clinical trials designed for such comparisons. Experts agree that increased durability while maintaining vision anatomy and perception is the gold standard of care for retinal disease therapies.

David Eichenbaum, MD raises a question about the drying efficacy of aflibercept 8 milligrams compared to aflibercept 2 mg in wet AMD. Seenu Hariprasad, MD responds, stating that there is good level-one evidence demonstrating that the second-generation agents, including aflibercept 8 mg, exhibit superior drying effects compared to the older generation agents like aflibercept 2 mg. He notes an increase in drying effect with the new generation agents and emphasizes the importance of drying in controlling vision outcomes.

This summary was AI-generated and edited for clarity.